Correction: Hamilton et al. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2017, 18, 2305

By sjmartinez • March 12, 2024

Hamilton N, Austin D, Márquez-Garbán D, Sanchez R, Chau B, Foos K, Wu Y, Vadgama J, Pietras R. Correction: Hamilton et al. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2017, 18, 2305. Int J Mol Sci. 2024 Feb 23;25(5):2579. doi: 10.3390/ijms25052579. Erratum for: Int J Mol Sci. 2017 Nov 02;18(11): PMID: 38474325.

Tags: Endocrinology, General Internal Medicine, Hematology/Oncology, King Drew Med Ctr, Publications

Rebuilding the foundation: recommendations from the Summit to Revitalize Primary Care (Rev PC)

Summit to Revitalize Primary Care Writing Committee*; Jerant A, Kravitz RL, Fenton JJ, Lyles CR, Grumbach K, Henderson MC, Ritley D, Brandt M, Cohen D,[...]

Reaching Veterans Most in Need: Evaluating Engagement in a National Telephone Lifestyle Coaching Program for Veterans

Clair K, Bean-Mayberry B, Chanfreau C, Hurley S, Pear E, Goldstein MG, Kim J, Raffa SD, Moin T, Finley EP, Hamilton A, Farmer MM. Reaching[...]

Efficacy and safety of relacorilant for the treatment of patients with Cushing’s syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study

Pivonello R, Arnaldi G, Auchus RJ, Badiu C, Busch RS, Cannavò S, Dischinger U, Dobri GA, Donegan DM, Elenkova A, Fazeli PK, Feelders RA, Garcia-Centeno[...]